In Depth 25 Sep 2023 Base editing hits the clinic in the U.S. Over the past couple of years, base editing, a recent offshoot of the heralded CRISPR/Cas 9 technology, has been doing its rounds in the biotech space. Now, base editing has finally set foot into clinical trials for the first time in the U.S.. American precision medicine company Beam Therapeutics treated its first patient with its […] September 25, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2023 U.S. approval for psychedelic drug MDMA nears after success in clinic The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes after Australia became the first country to allow doctors to prescribe the drug to those struggling with mental health disorders like PTSD and depression. Recognizing […] September 22, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm Known throughout history for being home to the iconic scene of Hollywood, in recent years Los Angeles has also become a thriving biotech hub, after years of playing second fiddle in the U.S. to the likes of South San Francisco and Boston. In this article, we take a look at five of the best Los […] September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Sep 2023 The biggest private biotech investments in August 2023 The companies Genesis Therapeutics, ADARx Pharmaceuticals, and Abcuro bagged the biggest biotech investments in August 2023. Around the world, companies focused on immunology, genetic disorders, and metabolic disorders attracted the biggest funding rounds. Overall, quite a lot of biotech fundraising took place in August 2023. As always, there were some big rounds within the U.S. […] September 4, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Aug 2023 Five North Carolina biotech companies making their mark North Carolina is home to Research Triangle Park, an R&D sanctuary situated between the cities of Raleigh and Durham, which just happens to be one of the biggest biotech hubs in the U.S., with a multitude of renowned companies. The southeastern state even rivals the likes of Boston, San Francisco, Los Angeles, and San Diego, […] August 30, 2023 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Aug 2023 Are these 10 biotech recruiters on your radar this year? The process of hunting for recruits can be a struggle for many companies, particularly when they have an ideal candidate in mind. And many at times, for the life science/biotech industry, due to the highly competitive landscape – for both recruiters and job seekers – hiring has been made more difficult. While some believe that […] August 29, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2023 Moleculin issues acute myeloid leukemia drug data Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […] July 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2023 Crossbow Therapeutics launches with $80M to target cancer Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […] July 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 30 Jun 2023Beyond Biotech podcast 52: Antiphospholipid syndrome June is Antiphospholipid Syndrome (APS) Awareness Month. APS is a rare autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy […] June 30, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2023 Key regulator of COVID viral receptor may be new drug target Entry of the SARS-CoV-2 virus into human tissues depends on the activity of a host gene that regulates production of a key viral receptor, according to a study published in the open access journal PLOS Biology by Madison Strine and Craig Wilen of Yale University, U.S., and colleagues. The finding provides important new information on […] June 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 Nordic Bioscience cancer biomarker gets FDA go ahead Danish biomarker company Nordic Bioscience says its PRO-C3 biomarker assay has received a Letter of Support (LoS) from the U.S. Food and Drug Administration (FDA). The letter acknowledges and supports further study of the PRO-C3 biomarker assay as a prognostic biomarker in tumor fibrosis studies. Nordic Bioscience has a successful track record of developing and […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2023 CellCentric receives FDA Fast Track designation for relapsed refractory multiple myeloma drug CellCentric has announced that the U.S. Food and Drug Administration (FDA) has granted its novel cancer drug, inobrodib, Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma. The FDA’s Fast Track designation is designed to aid the development of new treatments, expediting the review of drugs to treat serious conditions […] June 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email